北欧饮食模式与心脏代谢结局:前瞻性队列研究和随机对照试验的系统综述与荟萃分析
为更新EASD营养治疗临床实践指南,检索MEDLINE、EMBASE和Cochrane Library至2021年3月9日,纳入15项前瞻性队列研究(n=1,057,176)和6项RCT(n=717)。北欧饮食模式高依从性与总心血管疾病发病率、心血管死亡率、冠心病、卒中及2型糖尿病发病率的小幅重要降低相关,RCT中LDL-胆固醇等指标也有改善。证据确定性为低至高不等。
要点
- 前瞻性队列研究中,北欧饮食模式最高 vs 最低依从性的总心血管疾病发病率RR为0.93(95%CI 0.88, 0.99),p=0.01。
- RCT中北欧饮食模式使LDL-胆固醇平均降低0.26 mmol/l(95%CI -0.52, -0.00),p=0.05。
- 总心血管疾病发病率和LDL-胆固醇的证据确定性为低,主要因不精确性和不一致性降级。
核心结论
- 坚持北欧饮食模式与主要心血管疾病结局和糖尿病风险的小幅重要降低相关,LDL-胆固醇及其他中间心脏代谢危险因素的类似降低支持这一关联。
- 现有证据为北欧饮食模式对糖尿病患者或糖尿病高危人群的可能益处提供了总体良好的提示。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和The Cochrane Library从建库至2021年3月9日。
- 纳入随访≥1年的前瞻性队列研究和随访≥3周的RCT。
- 纳入15项前瞻性队列研究(n=1,057,176,41,708例心血管事件和13,121例糖尿病病例)和6项RCT(n=717)。
- 两名独立评审者提取数据并评估偏倚风险(纽卡斯尔-渥太华量表和Cochrane偏倚风险工具)。
- 使用GRADE方法评估证据确定性。
主要发现
- 前瞻性队列研究中,北欧饮食模式最高 vs 最低依从性的总心血管疾病发病率RR为0.93(95%CI 0.88, 0.99),p=0.01,存在显著异质性(I²=88%,pQ<0.001)。
- 前瞻性队列研究中,心血管死亡率、冠心病、卒中和2型糖尿病发病率也见相似或更大降低(p<0.05),且总心血管疾病发病率、心血管死亡率、冠心病、卒中和2型糖尿病发病率呈反向剂量反应梯度(p<0.05)。
- RCT中,北欧饮食模式使LDL-胆固醇平均降低0.26 mmol/l(95%CI -0.52, -0.00),pMD=0.05,存在显著异质性(I²=89%,pQ<0.01)。
- RCT中,非HDL-胆固醇、载脂蛋白B、胰岛素、体重、BMI和收缩压也见小幅重要或更大的降低(p<0.05);其他结局见微小降低或无效果。
- 证据确定性:总心血管疾病发病率和LDL-胆固醇为低;心血管死亡率、既定脂质目标、肥胖指标、血糖控制、血压和炎症为中至高度;所有其他结局为低,主要因不精确性和不一致性降级。
关键数值与推荐
- 前瞻性队列研究主要结局为总心血管疾病发病率,RCT主要结局为LDL-胆固醇。
- 前瞻性队列研究次要结局包括心血管死亡率、冠心病发病率和死亡率、卒中和死亡率及2型糖尿病发病率;RCT次要结局包括其他既定脂质目标、血糖控制标志物、肥胖指标、炎症标志物和血压。
- 未报告冠心病或卒中死亡率的研究。
临床怎么用
- 原文未据此给出推荐。
- 作者认为现有证据为北欧饮食模式对糖尿病患者或糖尿病高危人群的可能益处提供了总体良好的提示。
局限性
- 总心血管疾病发病率的证据存在显著异质性(I²=88%,pQ<0.001)。
- RCT中LDL-胆固醇的证据存在显著异质性(I²=89%,pQ<0.01)。
- 总心血管疾病发病率和LDL-胆固醇的证据确定性为低,主要因不精确性和不一致性降级。
- 所有其他结局的证据确定性为低,主要因不精确性和不一致性降级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Nordic dietary patterns that are high in healthy traditional Nordic foods may have a role in the prevention and management of diabetes. To inform the update of the EASD clinical practice guidelines for nutrition therapy, we conducted a systematic review and meta-analysis of Nordic dietary patterns and cardiometabolic outcomes. METHODS: We searched MEDLINE, EMBASE and The Cochrane Library from inception to 9 March 2021. We included prospective cohort studies and RCTs with a follow-up of ≥1 year and ≥3 weeks, respectively. Two independent reviewers extracted relevant data and assessed the risk of bias (Newcastle-Ottawa Scale and Cochrane risk of bias tool). The primary outcome was total CVD incidence in the prospective cohort studies and LDL-cholesterol in the RCTs. Secondary outcomes in the prospective cohort studies were CVD mortality, CHD incidence and mortality, stroke incidence and mortality, and type 2 diabetes incidence; in the RCTs, secondary outcomes were other established lipid targets (non-HDL-cholesterol, apolipoprotein B, HDL-cholesterol, triglycerides), markers of glycaemic control (HbA1c, fasting glucose, fasting insulin), adiposity (body weight, BMI, waist circumference) and inflammation (C-reactive protein), and blood pressure (systolic and diastolic blood pressure). The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence. RESULTS: We included 15 unique prospective cohort studies (n=1,057,176, with 41,708 cardiovascular events and 13,121 diabetes cases) of people with diabetes for the assessment of cardiovascular outcomes or people without diabetes for the assessment of diabetes incidence, and six RCTs (n=717) in people with one or more risk factor for diabetes. In the prospective cohort studies, higher adherence to Nordic dietary patterns was associated with 'small important' reductions in the primary outcome, total CVD incidence (RR for highest vs lowest adherence: 0.93 [95% CI 0.88, 0.99], p=0.01; substantial heterogeneity: I2=88%, pQ<0.001), and similar or greater reductions in the secondary outcomes of CVD mortality and incidence of CHD, stroke and type 2 diabetes (p<0.05). Inverse dose-response gradients were seen for total CVD incidence, CVD mortality and incidence of CHD, stroke and type 2 diabetes (p<0.05). No studies assessed CHD or stroke mortality. In the RCTs, there were small important reductions in LDL-cholesterol (mean difference [MD] -0.26 mmol/l [95% CI -0.52, -0.00], pMD=0.05; substantial heterogeneity: I2=89%, pQ<0.01), and 'small important' or greater reductions in the secondary outcomes of non-HDL-cholesterol, apolipoprotein B, insulin, body weight, BMI and systolic blood pressure (p<0.05). For the other outcomes there were 'trivial' reductions or no effect. The certainty of the evidence was low for total CVD incidence and LDL-cholesterol; moderate to high for CVD mortality, established lipid targets, adiposity markers, glycaemic control, blood pressure and inflammation; and low for all other outcomes, with evidence being downgraded mainly because of imprecision and inconsistency. CONCLUSIONS/INTERPRETATION: Adherence to Nordic dietary patterns is associated with generally small important reductions in the risk of major CVD outcomes and diabetes, which are supported by similar reductions in LDL-cholesterol and other intermediate cardiometabolic risk factors. The available evidence provides a generally good indication of the likely benefits of Nordic dietary patterns in people with or at risk for diabetes. REGISTRATION: ClinicalTrials.gov NCT04094194. FUNDING: Diabetes and Nutrition Study Group of the EASD Clinical Practice.
引用
- Massara P, Zurbau A, Glenn AJ, et al. Nordic dietary patterns and cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials. Diabetologia. 2022. PMID: 36008559. doi:10.1007/s00125-022-05760-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。